BioRestorative Therapies, Inc.(BRTX)Earnings, Financials & Key Ratios
BRTX•NASDAQ
$0.24
$2M mkt cap·Price updated May 6, 2026
AboutBioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.Show more
- Revenue$401K+175.0%
- EBITDA-$11M+24.5%
- Net Income-$9M+13.8%
- EPS (Diluted)-1.16+53.0%
- Gross Margin93%-7.0%
- EBITDA Margin-2834.45%+72.5%
- Operating Margin-2881.59%+72.4%
- Net Margin-2239.25%+68.7%
- ROE-96.89%+5.6%
- ROIC-100.39%+20.1%
BRTX Key Insights
BioRestorative Therapies, Inc. (BRTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 25.3%
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Shares diluted 84.1% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BRTX Price & Volume
BioRestorative Therapies, Inc. (BRTX) stock price & volume — 10-year historical chart
Loading chart...
BRTX Growth Metrics
BioRestorative Therapies, Inc. (BRTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-0.37%
5 Years25.27%
3 Years105.81%
TTM1.7%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-105.33%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-108.45%
Return on Capital
10 Years-136.13%
5 Years-136.13%
3 Years-130.03%
Last Year-124.68%
BRTX Peer Comparison
BioRestorative Therapies, Inc. (BRTX) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MESO | 2.04B | 15.81 | -18.82 | 191.39% | -5.94% | -17.1% | 0.21 | |
 XTNT | 80.8M | 0.58 | -4.81 | 28.44% | 1.32% | 3.77% | 0.82 | |
 MDXG | 543.76M | 3.66 | 11.44 | 19.99% | 7.88% | 12.86% | 0.09 | |
 RGEN | 7.09B | 125.76 | 146.23 | 16.36% | 6.73% | 2.46% | 0.33 | |
 CYTK | 9.22B | 74.84 | -11.44 | 376.56% | -7.84% | |||
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 CELH | 8.43B | 32.80 | 131.20 | 85.54% | 4.29% | 4.66% | 0.23 | |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare BRTX vs Peers
BioRestorative Therapies, Inc. (BRTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BRTX Income Statement
BioRestorative Therapies, Inc. (BRTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 36.35K | 81K | 111K | 130K | 77K | 46K | 119.8K | 145.8K | 401K | 383.4K |
| Revenue Growth % | -94.22% | 122.8% | 37.04% | 17.12% | -40.77% | -40.26% | 160.43% | 21.7% | 175.03% | 1.7% |
| Cost of Goods Sold | 102 | 259.26K | 0 | 0 | 0 | 0 | 0 | 0 | 28.07K | 78.17K |
| COGS % of Revenue | 0.28% | 320.07% | - | - | - | - | - | - | 7% | - |
| Gross Profit | 36.25K▲ 0% | -178.26K▼ 591.7% | 111K▲ 162.3% | 130K▲ 17.1% | 77K▼ 40.8% | 46K▼ 40.3% | 119.8K▲ 160.4% | 145.8K▲ 21.7% | 372.93K▲ 155.8% | 305.23K▲ 0% |
| Gross Margin % | 99.72% | -220.07% | 100% | 100% | 100% | 100% | 100% | 100% | 93% | 79.61% |
| Gross Profit Growth % | -90.13% | -591.71% | 162.27% | 17.12% | -40.77% | -40.26% | 160.43% | 21.7% | 155.78% | - |
| Operating Expenses | 7.83M | 8.46M | 7.76M | 8.56M | 2.83M | 26.35M | 19.09M | 15.37M | 11.93M | 14.82M |
| OpEx % of Revenue | 21547.27% | 10438.62% | 6989.78% | 6586.16% | 3674.12% | 57291.03% | 15938.08% | 10539.49% | 2974.59% | - |
| Selling, General & Admin | 4.95M | 6.3M | 6.25M | 6.84M | 1.95M | 25.62M | 15.58M | 11.33M | 6.58M | 6.62M |
| SG&A % of Revenue | 13615.59% | 7781.3% | 5626.58% | 5261.28% | 2535.39% | 55706.12% | 13005.4% | 7772.28% | 1640.75% | - |
| Research & Development | 2.88M | 2.15M | 1.51M | 1.72M | 876.83K | 729.06K | 3.51M | 4.03M | 5.35M | 8.19M |
| R&D % of Revenue | 7931.68% | 2657.32% | 1363.2% | 1324.88% | 1138.74% | 1584.91% | 2932.68% | 2767.21% | 1333.84% | - |
| Other Operating Expenses | -46.6K | -59.94K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -7.8M▲ 0% | -8.37M▼ 7.4% | -7.65M▲ 8.7% | -8.43M▼ 10.3% | -2.75M▲ 67.4% | -26.31M▼ 855.9% | -18.97M▲ 27.9% | -15.22M▲ 19.8% | -11.56M▲ 24.1% | -14.51M▲ 0% |
| Operating Margin % | -21447.55% | -10338.62% | -6889.78% | -6486.16% | -3574.12% | -57191.03% | -15838.08% | -10439.49% | -2881.59% | -3785.07% |
| Operating Income Growth % | -8.74% | -7.4% | 8.68% | -10.26% | 67.36% | -855.93% | 27.88% | 19.78% | 24.08% | - |
| EBITDA | -7.54M | -8.12M | -7.41M | -8.21M | -2.6M | -26.22M | -18.85M | -15.06M | -11.37M | -14.3M |
| EBITDA Margin % | -20736.71% | -10018.55% | -6673.23% | -6318.89% | -3376.77% | -56997.32% | -15737.46% | -10325.82% | -2834.45% | -3730.95% |
| EBITDA Growth % | -8.37% | -7.64% | 8.72% | -10.9% | 68.35% | -908.37% | 28.09% | 20.15% | 24.5% | -20.16% |
| D&A (Non-Cash Add-back) | 258.43K | 259.26K | 240.37K | 217.45K | 151.96K | 89.11K | 120.55K | 165.74K | 189.06K | 207.52K |
| EBIT | -7.87M | -8.36M | -9.3M | -9.51M | -9.63M | -26.31M | -18.86M | -15.14M | -11.56M | -13.19M |
| Net Interest Income | -763.94K | -1.09M | -3.22M | -5.14M | -1.64M | -1.82M | 11.65K | 552.29K | 616.08K | 350.61K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 11.65K | 552.29K | 616.08K | 350.61K |
| Interest Expense | 763.94K | 1.09M | 3.22M | 5.14M | 1.64M | 1.82M | 0 | 0 | 0 | 0 |
| Other Income/Expense | -839.03K | -1.07M | -4.87M | -6.22M | -8.52M | -18M | 5.75M | 4.8M | 2.58M | 1.84M |
| Pretax Income | -8.64M▲ 0% | -9.44M▼ 9.4% | -12.52M▼ 32.5% | -14.65M▼ 17.0% | -11.27M▲ 23.0% | -44.3M▼ 293.0% | -13.22M▲ 70.2% | -10.42M▲ 21.2% | -8.98M▲ 13.8% | -12.67M▲ 0% |
| Pretax Margin % | -23755.44% | -11660.07% | -11277.3% | -11267.61% | -14639.85% | -96311.51% | -11036.98% | -7145.2% | -2239.25% | -3304.77% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -8.64M▲ 0% | -9.44M▼ 9.4% | -12.52M▼ 32.5% | -14.65M▼ 17.0% | -11.27M▲ 23.0% | -44.3M▼ 293.0% | -13.22M▲ 70.2% | -10.42M▲ 21.2% | -8.98M▲ 13.8% | -12.67M▲ 0% |
| Net Margin % | -23755.44% | -11660.07% | -11277.3% | -11267.61% | -14639.85% | -96311.51% | -11036.98% | -7145.2% | -2239.25% | -3304.77% |
| Net Income Growth % | -9% | -9.36% | -32.54% | -17.02% | 23.04% | -293.01% | 70.16% | 21.21% | 13.81% | -105.33% |
| Net Income (Continuing) | -8.64M | -9.44M | -12.52M | -14.65M | -11.27M | -44.3M | -13.22M | -10.42M | -8.98M | -12.67M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -7356.30▲ 0% | -6181.06▲ 16.0% | -4269.37▲ 30.9% | -3217.82▲ 24.6% | -28.56▲ 99.1% | -37.30▼ 30.6% | -3.65▲ 90.2% | -2.47▲ 32.3% | -1.16▲ 53.0% | -1.39▲ 0% |
| EPS Growth % | 23.22% | 15.98% | 30.93% | 24.63% | 99.11% | -30.6% | 90.21% | 32.33% | 53.04% | -108.45% |
| EPS (Basic) | -7356.30 | -6181.06 | -4269.37 | -3217.82 | -28.56 | -37.30 | -3.65 | -2.47 | -1.16 | - |
| Diluted Shares Outstanding | 1.17K | 1.53K | 2.93K | 5.57K | 394.7K | 1.19M | 3.62M | 4.22M | 7.76M | 9.12M |
| Basic Shares Outstanding | 1.17K | 1.53K | 2.93K | 5.57K | 394.7K | 1.19M | 3.62M | 4.22M | 7.76M | 9.12M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BRTX Balance Sheet
BioRestorative Therapies, Inc. (BRTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 61.68K | 519.71K | 180.99K | 68.86K | 3.19M | 21.47M | 15.13M | 11.39M | 11.14M | 4.7M |
| Cash & Short-Term Investments | 31.82K | 451.68K | 117.52K | 1.66K | 3.06M | 21.03M | 14.75M | 11.07M | 10.73M | 4.49M |
| Cash Only | 31.82K | 451.68K | 117.52K | 1.66K | 3.06M | 21.03M | 1.71M | 884.38K | 547.89K | 602.44K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 13.04M | 10.18M | 10.18M | 3.89M |
| Accounts Receivable | 6K | 38K | 29K | 32K | 17K | 5K | 16K | 19.3K | 188.4K | 13.4K |
| Days Sales Outstanding | 60.24 | 171.23 | 95.36 | 89.85 | 80.58 | 39.67 | 48.75 | 48.32 | 171.49 | 57.55 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 30.03K | 34.46K | 0 | 0 | 0 | 0 | 0 | 223.23K | 196.75K |
| Total Non-Current Assets | 1.52M | 1.24M | 1.01M | 1.4M | 1.16M | 985.54K | 1.31M | 1.22M | 1.14M | 942.69K |
| Property, Plant & Equipment | 508.59K | 327.85K | 175.24K | 658.3K | 495.76K | 395.8K | 502.76K | 507.5K | 362.94K | 309.5K |
| Fixed Asset Turnover | 0.07x | 0.25x | 0.63x | 0.20x | 0.16x | 0.12x | 0.24x | 0.29x | 1.10x | 1.11x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 963.85K | 888.95K | 814.06K | 739.16K | 664.27K | 589.74K | 803.44K | 713.69K | 623.95K | 556.63K |
| Long-Term Investments | 45.9K | 22.1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 45.9K | 22.1K | 22.1K | 0 | 0 | 0 | 1 | 0 | 148.7K | 225.25K |
| Total Assets | 1.58M▲ 0% | 1.76M▲ 11.3% | 1.19M▼ 32.2% | 1.47M▲ 23.0% | 4.35M▲ 196.5% | 22.45M▲ 416.5% | 16.43M▼ 26.8% | 12.61M▼ 23.3% | 12.28M▼ 2.6% | 5.64M▲ 0% |
| Asset Turnover | 0.02x | 0.05x | 0.09x | 0.09x | 0.02x | 0.00x | 0.01x | 0.01x | 0.03x | 0.04x |
| Asset Growth % | -21.67% | 11.3% | -32.2% | 22.97% | 196.46% | 416.52% | -26.81% | -23.26% | -2.63% | -153.55% |
| Total Current Liabilities | 5.84M | 8.35M | 9.25M | 13.72M | 1.04M | 363.82K | 5.98M | 2.61M | 3.75M | 3.44M |
| Accounts Payable | 2.28M | 2.45M | 1.89M | 1.95M | 118.85K | 50.83K | 170.9K | 189.39K | 483.07K | 859.9K |
| Days Payables Outstanding | 1000K | 3.46K | - | - | - | - | - | - | 6.28K | 2.98K |
| Short-Term Debt | 1.86M | 3.47M | 3.63M | 7.23M | 0 | 58.97K | 0 | 162.32K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 2.21M | 2.64M | 3.62M | 0 | 0 | 0 | 0 | 0 | 150K |
| Other Current Liabilities | 821.74K | 216.07K | 1.09M | -2.22M | 657.6K | 106.6K | 5.54M | 2.26M | 2.52M | 2.04M |
| Current Ratio | 0.01x | 0.06x | 0.02x | 0.01x | 3.05x | 59.01x | 2.53x | 4.37x | 2.97x | 2.97x |
| Quick Ratio | 0.01x | 0.06x | 0.02x | 0.01x | 3.05x | 59.01x | 2.53x | 4.37x | 2.97x | 2.97x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -2.92K |
| Total Non-Current Liabilities | 735.44K | 241.87K | 578.53K | 521.89K | 4.63M | 492.68K | 162.32K | 0 | 0 | 0 |
| Long-Term Debt | 297.76K | 194.28K | 523.89K | 0 | 4.27M | 191.03K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 521.89K | 363.52K | 301.64K | 162.32K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 437.68K | 47.59K | 54.64K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 6.58M | 8.6M | 9.83M | 14.24M | 5.68M | 856.5K | 6.14M | 2.61M | 3.75M | 3.44M |
| Total Debt | 2.16M | 3.66M | 4.15M | 7.84M | 4.79M | 670.7K | 301.64K | 162.32K | 0 | 0 |
| Net Debt | 2.12M | 3.21M | 4.03M | 7.84M | 1.73M | -20.36M | -1.41M | -722.06K | -547.89K | -602.44K |
| Debt / Equity | - | - | - | - | - | 0.03x | 0.03x | 0.02x | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.04x |
| Interest Coverage | -10.21x | -7.70x | -2.37x | -1.64x | -1.68x | -14.49x | - | - | - | - |
| Total Equity | -5M▲ 0% | -6.84M▼ 36.7% | -8.64M▼ 26.4% | -12.78M▼ 47.9% | -1.33M▲ 89.6% | 21.6M▲ 1722.0% | 10.29M▼ 52.4% | 10M▼ 2.8% | 8.53M▼ 14.7% | 2.21M▲ 0% |
| Equity Growth % | -27.93% | -36.72% | -26.39% | -47.85% | 89.58% | 1722.01% | -52.35% | -2.78% | -14.72% | -205.4% |
| Book Value per Share | -4259.18 | -4474.19 | -2947.15 | -2294.15 | -3.37 | 18.18 | 2.84 | 2.37 | 1.10 | 0.24 |
| Total Shareholders' Equity | -5M | -6.84M | -8.64M | -12.78M | -1.33M | 21.6M | 10.29M | 10M | 8.53M | 2.21M |
| Common Stock | 4.7K | 6.11K | 11.73K | 7.79K | 72 | 353 | 369 | 471 | 692 | 797 |
| Retained Earnings | -41.96M | -51.4M | -63.92M | -78.57M | -89.84M | -134.15M | -136.28M | -146.7M | -155.68M | -166.71M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BRTX Cash Flow Statement
BioRestorative Therapies, Inc. (BRTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5M | -3.85M | -5.1M | -6.92M | -1.96M | -3.33M | -5.91M | -6.43M | -8.23M | -8.23M |
| Operating CF Margin % | -13760.62% | -4757.8% | -4598.76% | -5322.1% | -2550.99% | -7238.93% | -4935.81% | -4410.3% | -2052.46% | - |
| Operating CF Growth % | -60.24% | 22.96% | -32.46% | -35.54% | 71.61% | -69.52% | -77.58% | -8.75% | -27.99% | -167.41% |
| Net Income | -8.64M | -9.44M | -12.52M | -14.65M | -11.27M | -44.3M | -13.22M | -10.42M | -8.98M | -12.67M |
| Depreciation & Amortization | 258.43K | 259.26K | 240.37K | 217.36K | 121.38K | 89.11K | 120.55K | 165.74K | 189.06K | 207.52K |
| Stock-Based Compensation | 2.54M | 3.6M | 2.4M | 1.66M | 691.7K | 23.11M | 12.61M | 7.78M | 2.81M | 2.65M |
| Deferred Taxes | 87.27K | -17K | 1.65M | 1.11M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 570.21K | 926.45K | 3.17M | 4.21M | 7.92M | 17.45M | -5.44M | -4.48M | -2.28M | -1.41M |
| Working Capital Changes | 180.93K | 821.33K | -45.78K | 539.85K | 572.35K | 324.69K | 14.14K | 515.33K | 28.65K | 502.64K |
| Change in Receivables | 87.38K | -32K | 9K | -3K | 15K | 12K | -11K | -3.3K | -169.1K | 151.6K |
| Change in Inventory | 5.99M | 655.29K | 9.54M | 423.65K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -113.15K | 185.96K | -516.12K | 97.1K | 84.63K | -68.02K | 120.08K | 18.49K | 293.68K | 438.76K |
| Cash from Investing | -188.76K | -3.62K | -12.87K | -35.63K | 0 | -30.66K | -13.4M | 3.25M | 514.53K | 8.03M |
| Capital Expenditures | -188.76K | -3.62K | -12.87K | -35.63K | 0 | -30.66K | -265.22K | -171.04K | -106.19K | -48.83K |
| CapEx % of Revenue | 519.22% | 4.47% | 11.59% | 27.41% | - | 66.65% | 221.39% | 117.31% | 26.48% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | -175K | 0 | 0 | 0 |
| Cash from Financing | 5.06M | 4.28M | 4.78M | 6.84M | 5.03M | 21.32M | 0 | 2.35M | 7.38M | 1.81M |
| Debt Issued (Net) | 1.42M | 2.21M | 4.19M | 5.18M | 5.52M | 250K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 175K | 1000K | 10K | 1000K | 0 | 1000K | 0 | 1.93M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 140.87K | 981.25K | 414.17K | 0 | -500K | 0 | 0 | 0 | 7.38M | -206.02K |
| Net Change in Cash | -134.73K▲ 0% | 419.86K▲ 411.6% | -334.16K▼ 179.6% | -115.86K▲ 65.3% | 3.06M▲ 2743.7% | 17.96M▲ 486.4% | -19.31M▼ 207.5% | -829.39K▲ 95.7% | -336.49K▲ 59.4% | -887K▲ 0% |
| Free Cash Flow | -5.19M▲ 0% | -3.86M▲ 25.7% | -5.12M▼ 32.7% | -6.95M▼ 35.9% | -1.96M▲ 71.8% | -3.36M▼ 71.1% | -6.35M▼ 89.1% | -6.6M▼ 3.9% | -8.34M▼ 26.3% | -10.77M▲ 0% |
| FCF Margin % | -14279.85% | -4762.27% | -4610.36% | -5349.51% | -2550.99% | -7305.58% | -5303.27% | -4527.61% | -2078.94% | -2809.2% |
| FCF Growth % | -44% | 25.7% | -32.67% | -35.89% | 71.75% | -71.09% | -89.06% | -3.9% | -26.29% | -37.73% |
| FCF per Share | -4422.01 | -2524.50 | -1745.39 | -1248.76 | -4.98 | -2.83 | -1.76 | -1.56 | -1.07 | -1.07 |
| FCF Conversion (FCF/Net Income) | 0.58x | 0.41x | 0.41x | 0.47x | 0.17x | 0.08x | 0.45x | 0.62x | 0.92x | 0.85x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BRTX Key Ratios
BioRestorative Therapies, Inc. (BRTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | - | - | -437.23% | -82.93% | -102.66% | -96.89% | -574.11% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -2410.7% | -281.26% | -125.72% | -100.39% | -100.39% |
| Gross Margin | 99.72% | -220.07% | 100% | 100% | 100% | 100% | 100% | 100% | 93% | 79.61% |
| Net Margin | -23755.44% | -11660.07% | -11277.3% | -11267.61% | -14639.85% | -96311.51% | -11036.98% | -7145.2% | -2239.25% | -3304.77% |
| Debt / Equity | - | - | - | - | - | 0.03x | 0.03x | 0.02x | - | 0.00x |
| Interest Coverage | -10.21x | -7.70x | -2.37x | -1.64x | -1.68x | -14.49x | - | - | - | - |
| FCF Conversion | 0.58x | 0.41x | 0.41x | 0.47x | 0.17x | 0.08x | 0.45x | 0.62x | 0.92x | 0.85x |
| Revenue Growth | -94.22% | 122.8% | 37.04% | 17.12% | -40.77% | -40.26% | 160.43% | 21.7% | 175.03% | 1.7% |
BRTX Frequently Asked Questions
BioRestorative Therapies, Inc. (BRTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BioRestorative Therapies, Inc. (BRTX) reported $0.4M in revenue for fiscal year 2024.
BioRestorative Therapies, Inc. (BRTX) grew revenue by 175.0% over the past year. This is strong growth.
BioRestorative Therapies, Inc. (BRTX) reported a net loss of $12.7M for fiscal year 2024.
Dividend & Returns
BioRestorative Therapies, Inc. (BRTX) has a return on equity (ROE) of -96.9%. Negative ROE indicates the company is unprofitable.
BioRestorative Therapies, Inc. (BRTX) had negative free cash flow of $10.8M in fiscal year 2024, likely due to heavy capital investments.
Explore More BRTX
BioRestorative Therapies, Inc. (BRTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates